RICHARD GAYNOR
CIK 1741284 · President of R&D · last filed 2026-05-22
RICHARD GAYNOR is a President of R&D who has filed 33 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for ALKS, was dated May 22, 2026. Across all open-market trades the lifetime net is −$189.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.62M
4
33
-$189.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 37,226 | $44.28 | $1.65M | $0 | 16 | 2026-05-22 |
| ZLAB | Director | 56,630 | $17.07 | $966.7K | -$103.7K | 7 | 2026-03-19 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2022-06-16 |
| Neon Therapeutics, Inc. (NTGN) Delisted | President of R&D | 0 | — | — | -$85.4K | 7 | 2020-05-06 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | ALKS | Mixed | +4,667 | -$54.5K | EDGAR |
| 2026-05-22 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2026-03-19 | ZLAB | Buy (P) | +1,731 | $32.7K | EDGAR |
| 2025-06-23 | ZLAB | Grant (A) | +10,831 | $0 | EDGAR |
| 2025-06-02 | ALKS | Mixed | +6,089 | -$58.9K | EDGAR |
| 2025-05-23 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2025-03-06 | ZLAB | Sell (S) | −2,500 | -$87.7K | EDGAR |
| 2024-09-05 | ZLAB | Sell (S) | −2,500 | -$48.8K | EDGAR |
| 2024-07-01 | ALKS | Mixed | +4,639 | -$35.3K | EDGAR |
| 2024-06-20 | ZLAB | Grant (A) | +21,253 | $0 | EDGAR |